| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 309.08% | £286,358.08 |
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 288.95% | £272,265.94 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 214.16% | £219,914.88 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 31.65% | £92,152.71 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 22.19% | £85,529.59 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 2.36% | £71,650.76 |
| Lord Mance |
|
Stryker / NYQ:SYK | -1.81% | £68,729.82 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -5.02% | £66,487.78 |
| Baroness Deech |
|
Smith & Nephew / NYQ:SNN | -7.44% | £64,792.23 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -9.08% | £63,643.95 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -44.94% | £38,540.27 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -64.65% | £24,743.20 |